|Application ||WB, IHC-F, FC, E|
|Calculated MW||187148 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein A|
|Immunogen||Purified human iC3b|
|Shelf Life||18 months from date of despatch.|
|Other Names||Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, Complement C3 beta chain, C3-beta-c, C3bc, Complement C3 alpha chain, C3a anaphylatoxin, Acylation stimulating protein, ASP, C3adesArg, Complement C3b alpha' chain, Complement C3c alpha' chain fragment 1, Complement C3dg fragment, Complement C3g fragment, Complement C3d fragment, Complement C3f fragment, Complement C3c alpha' chain fragment 2, C3, CPAMD1|
|Target/Specificity||ABD11830 recognises 42kDa human inactive complement component 3b (iC3b) neoantigen present in blood serum. Cleavage of C3b into iC3b by the protease factor I, in the presence of cofactors, changes the structure and resulting binding properties, preventing binding by complement factor B and properdin. This prevents further progression of the complement pathway, providing another mechanism by which the complement pathway may be regulated. iC3b is thought to play a role in inducing tolerance, binding complement receptor type 3 on antigen presenting cells and stimulating them to produce transforming growth factor beta2 and interleukin-10. It is thought to stimulate B-cells via the CD21 receptor providing a link between the innate and adaptive immune responses. Additionally iC3b acts as an opsonin which is recognised by complement receptor 3 expressed on leukocytes or complement receptor of the immunoglobulin superfamily (CRIg) on Kupffer cells, stimulating phagocytosis of the tagged cells. iC3b levels are often elevated in diseases such as Systemic Lupus Erythematosis and Rheumatoid arthritis.|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human iC3b (Neoantigen) Antibody, clone 013III-1.16 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Janssena, B. et al. (2007) Structural insights into the central complement component C3. Molecular Immunology. 44: 3-10. 2. Bergmann-Leitner, E. et al. (2006) Complement 3d: From molecular adjuvant to target of immune escape mechanisms. Clinical Immunology121: 177-185.3. Sohn, J. H. et al. (2003) Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nature Medicine 9: 206-212.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.